- Trials with a EudraCT protocol (28)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (13)
28 result(s) found for: MSA.
Displaying page 1 of 2.
EudraCT Number: 2018-000506-34 | Sponsor Protocol Number: EMERA006 | Start Date*: 2019-02-04 |
Sponsor Name:NBMI Science Ltd. | ||
Full Title: EMERA006- A pilot, exploratory, randomised, placebo-controlled, double blinded, cross-over, Phase 2a study to explore efficacy and safety of NBMI treatment in patients with Progressive Supranuclear... | ||
Medical condition: PSP or MSA | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: SI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-014644-11 | Sponsor Protocol Number: MSA-RAS-202 | Start Date*: 2009-12-08 | |||||||||||
Sponsor Name:Teva Pharmaceutical Industries Ltd | |||||||||||||
Full Title: A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy o... | |||||||||||||
Medical condition: Multiple System Atrophy of the Parkinsonian Subtype | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) ES (Completed) HU (Completed) AT (Completed) NL (Completed) IT (Completed) PT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016377-15 | Sponsor Protocol Number: MSA_LITIO_13 | Start Date*: 2009-10-26 | |||||||||||
Sponsor Name:UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II | |||||||||||||
Full Title: DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO TEST THE EFFICACY, SAFETY AND TOLERABILITY OF LITHIUM IN MULTIPLE SYSTEM ATROPHY | |||||||||||||
Medical condition: Muliple system atrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003231-29 | Sponsor Protocol Number: ATH434-201 | Start Date*: 2022-07-26 | |||||||||||
Sponsor Name:Alterity Therapeutics Limited | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in Multiple System Atrophy | |||||||||||||
Medical condition: Multiple System Atrophy (MSA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) FR (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000122-26 | Sponsor Protocol Number: 125591 | Start Date*: 2020-05-11 | |||||||||||
Sponsor Name:University College London (UCL) | |||||||||||||
Full Title: A Phase IIa, open label, single-site, 48 week randomised controlled trial evaluating the safety and efficacy of Exenatide once-weekly in the treatment of patients with Multiple System Atrophy | |||||||||||||
Medical condition: Multiple System Atrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001100-38 | Sponsor Protocol Number: BHV3241-301 | Start Date*: 2019-12-13 | |||||||||||
Sponsor Name:Biohaven Pharmaceuticals, Inc | |||||||||||||
Full Title: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study) | |||||||||||||
Medical condition: Multiple System Atrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003289-15 | Sponsor Protocol Number: 0169 | Start Date*: 2019-05-08 |
Sponsor Name:Theravance Biopharma Ireland Limited | ||
Full Title: A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled,Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Auton... | ||
Medical condition: Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) EE (Completed) DE (Completed) DK (Completed) AT (Completed) HU (Completed) PL (Completed) ES (Ongoing) BG (Completed) PT (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003941-41 | Sponsor Protocol Number: 0170 | Start Date*: 2019-08-09 |
Sponsor Name:Theravance Biopharma Ireland Limited | ||
Full Title: A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure | ||
Medical condition: Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) EE (Prematurely Ended) PL (Completed) ES (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) BG (Prematurely Ended) HU (Completed) PT (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-018157-23 | Sponsor Protocol Number: D0490C00014 | Start Date*: 2010-11-30 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Treatment, Adaptive Design Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics ... | |||||||||||||
Medical condition: Multiple system atrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000928-18 | Sponsor Protocol Number: PROMESA | Start Date*: 2013-11-21 |
Sponsor Name:Hospital of the Ludwig-Maximilians-University of Munich | ||
Full Title: Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atr... | ||
Medical condition: Progression of patients with Multiple System Atrophy (MSA) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-004145-16 | Sponsor Protocol Number: Z7219K01 | Start Date*: 2019-07-24 | |||||||||||
Sponsor Name:Zambon SpA | |||||||||||||
Full Title: A 12-weeks, multicentre, randomized, double-blind, placebo-controlled, exploratory, pilot study to evaluate the safety and efficacy of safinamide 200 mg once daily, as add-on therapy, in patients w... | |||||||||||||
Medical condition: Parkinsonian variant of Multiple System Atrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004922-26 | Sponsor Protocol Number: 0720101 | Start Date*: 2008-02-12 | |||||||||||
Sponsor Name:CHU Toulouse | |||||||||||||
Full Title: Evaluation de l’effet de la fluoxétine chez le patient atteint d’atrophie multi-systématisée : Etude randomisée en double-insu versus placebo. | |||||||||||||
Medical condition: atrophie multisystématisée | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004902-13 | Sponsor Protocol Number: D0490C00023 | Start Date*: 2015-04-09 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positr... | |||||||||||||
Medical condition: Multiple system atrophy (MSA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FI (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002855-26 | Sponsor Protocol Number: Droxidopa-301 | Start Date*: 2008-10-01 |
Sponsor Name:Chelsea Therapeutics Inc | ||
Full Title: A Multi-Centre, Double-Blind, Placebo-Controlled, Parallel-Group Induction-Design Study to assess the Clinical Effect of Droxidopa in Subjects with Primary Autonomic Failure, Dopamine Beta Hydroxyl... | ||
Medical condition: Symptomatic neurogenic orthostatic hypotension (NOH) in patients with Primary Autonomic Failure (Pharmacodynamic, MSA and PAF), DBH deficiency and Non-Diabetic Neuropathy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) CZ (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-012449-48 | Sponsor Protocol Number: ALS-8-09-A-101 | Start Date*: 2009-11-09 |
Sponsor Name:Air Liquide Santé International | ||
Full Title: „Sympathetic neural outflow during Xenon anesthesia in humans“ | ||
Medical condition: We would like to frame the thesis, that a general, inhalative Xenon anesthesia (1 MAC) does not effect the sympathetic outflow and the sympathetic baroreflex reagibility under spontaneous breathing... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-000336-28 | Sponsor Protocol Number: TAK-341-2001 | Start Date*: 2022-10-21 | |||||||||||
Sponsor Name:Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple... | |||||||||||||
Medical condition: Multiple System Atrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005673-60 | Sponsor Protocol Number: Droxidopa-302 | Start Date*: 2009-04-22 |
Sponsor Name:Chelsea Therapeutics Inc | ||
Full Title: A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP WITHDRAWAL-DESIGN STUDY TO ASSESS THE CLINICAL EFFECT OF DROXIDOPA IN SUBJECTS WITH PRIMARY AUTONOMIC FAILURE, DOPAMINE ... | ||
Medical condition: Symptomatic neurogenic orthostatic hypotension (NOH) in patients with Primary Autonomic Failure (PD, MSA and PAF), DBH deficiency and Non-Diabetic Neuropathy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-005701-22 | Sponsor Protocol Number: Droxidopa-303 | Start Date*: 2009-04-13 |
Sponsor Name:Chelsea Therapeutics Inc | ||
Full Title: A MULTI-CENTER, OPEN-LABEL STUDY, WITH A TWO WEEK RANDOMIZED, PLACEBO-CONTROLLED, WITHDRAWAL PERIOD, TO ASSESS THE LONG-TERM SAFETY AND CLINICAL BENEFIT OF DROXIDOPA IN SUBJECTS WITH PRIMARY AUTONO... | ||
Medical condition: Symptomatic neurogenic orthostatic hypotension (NOH) in patients with Primary Autonomic Failure (PD, MSA and PAF), DBH deficiency and Non-Diabetic Neuropathy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-002425-30 | Sponsor Protocol Number: 0171 | Start Date*: 2020-03-17 |
Sponsor Name:Theravance Biopharma Ireland Limited | ||
Full Title: A Phase 3, 182-week, Open-Label, Extension Study to Investigate the Safety and Tolerability Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension (symptomatic nOH) in Subjects... | ||
Medical condition: Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) ES (Prematurely Ended) PL (Completed) EE (Completed) FR (Completed) PT (Prematurely Ended) AT (Prematurely Ended) BG (Prematurely Ended) DE (Prematurely Ended) HU (Completed) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2021-005499-20 | Sponsor Protocol Number: RM21 | Start Date*: 2022-07-05 |
Sponsor Name:Research Maatschap Cardiologen Rotterdam Zuid | ||
Full Title: COMPARE STEMI ONE- Comparison Of reduced DAPT followed by P2Y12 inhibitor Monotherapy with Prasugrel vs stAndard Regimen in STEMI patients treated with OCT-guided vs aNgio-guided completE revascul... | ||
Medical condition: ST elevated myocard infarction followed by PCI | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) DE (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
